ESR1 and breast carcinoma: Since deregulation of ERα activity is involved in breast cancer development and ERα is a target of breast cancer therapies, these results provide the rationale to a new approach based on the inhibition of receptor dimerization, mediated by protein/protein interaction stabilizers such as FC.